ClinicalTrials.gg
CompletedNCT01159912Updated Nov 9, 2017Results posted

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

A Phase 3 interventional study of Fluticasone propionate and Fluticasone furoate in Asthma, sponsored by GlaxoSmithKline. Completed at 82 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
15th of 40
350 · median 102
Started
2010
with 6 others
Phase 3
14 of 40
none open now
Registered
15th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 15th largest by enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 15th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.

Read the detailed description

This is a multi-center, randomized, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of Fluticasone Furoate Inhalation Powder 100mcg once daily and Fluticasone Propionate Inhalation Powder 250mcg twice daily with Placebo. Subjects will participate in the study for up to a maximum of 29 weeks (including screening, treatment and follow-up contact). The primary endpoint consists of change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at the end of the 24 week treatment period. The nominated powered secondary endpoint is the change from baseline in the percentage of rescue-free 24 hour periods during the 24-week treatment period. Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry and urine cortisol excretion. For subjects who have consented for pharmacogenetics, a blood sample will also be taken for pharmacogenetic analysis.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone propionate
  • Fluticasone furoate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Outpatient at least 12 years of age
  • Both genders; females of child bearing potential must be willing to use approved method
  • Pre-bronchodilator of 40-90% predicted
  • Reversibility FEV1 of at least 12% and 200mLs
  • Current asthma therapy that includes an inhaled for at least 4 weeks prior to first visit

Exclusion criteria

Exclusion Criteria:

  • History of life threatening asthma
  • Respiratory infection or candidiasis
  • Asthma exacerbation within 6 months prior to first visit
  • Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drug , medications related to study drugs
  • Taking another medication or medication prohibited for use during this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate OD and Placebo BID

    Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks

    Drug: Fluticasone furoate · Drug: Placebo

  • Active comparator
    Fluticasone Propionate BID and Placebo OD

    Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks

    Drug: Fluticasone propionate · Drug: Placebo

  • Placebo comparator
    Placebo only BID

    Placebo inhalation powder twice daily for 24 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the clinic visit at the end of the dosing interval. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods at the End of the 24-week Treatment Period

    The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Week 24

  2. Mean Change From Baseline in Daily Trough Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Trough evening PEF is the PM PEF measured approximately 24 hours after the last evening administration of study drug. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 12 and Week 24

  3. Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 12 and Week 24

  4. Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods at the End of the 24-week Treatment Period

    The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: Baseline and Week 24

  5. Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24

    The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the ages of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Weeks 12 and 24 minus the total score at Baseline.

    Time frame: Baseline, Week 12, and Week 24

07

Results

Posted Aug 8, 2013

Participant flow

One participant received treatment (placebo) but was not randomized. Thus, 350 participants were enrolled in the study; however, only 349 were randomized.

Participant flow — Overall Study
MilestonePlaceboFF 100 µg ODFP 250 µg BID
Started115114114
Completed759288
Not completed402226
Withdrew: Adverse event223
Withdrew: Lack of efficacy231514
Withdrew: Protocol violation123
Withdrew: Lost to follow-up400
Withdrew: Physician decision003
Withdrew: Withdrawal by subject1033

Outcome measures

PrimaryMean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the clinic visit at the end of the dosing interval. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Liters
Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period
LitersPlaceboFF 100 µg ODFP 250 µg BID
Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period0.015 ± 0.03940.161 ± 0.03980.159 ± 0.0406
Statistical analysis
  • Placebo vs FF 100 µg OD · ANCOVA · p = 0.009 · Mean difference (final values): 0.146 · 95% CI 0.036 to 0.257
  • Placebo vs FP 250 µg BID · ANCOVA · p = 0.011 · Median difference (final values): 0.145 · 95% CI 0.033 to 0.257
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods at the End of the 24-week Treatment Period

The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods at the End of the 24-week Treatment Period
Percentage of rescue-free 24-hr periodsPlaceboFF 100 µg ODFP 250 µg BID
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods at the End of the 24-week Treatment Period6.5 ± 2.8221.3 ± 2.8524.3 ± 2.83
SecondaryMean Change From Baseline in Daily Trough Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Trough evening PEF is the PM PEF measured approximately 24 hours after the last evening administration of study drug. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 12 and Week 24
Reported as:
Least squares mean · Liters/minute (L/min)
Mean Change From Baseline in Daily Trough Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
Liters/minute (L/min)PlaceboFF 100 µg ODFP 250 µg BID
PM PEF, Week 1 to 120.4 ± 3.252.2 ± 3.284.8 ± 3.28
PM PEF, Week 1 to 24-1.3 ± 3.361.5 ± 3.394.3 ± 3.40
SecondaryMean Change From Baseline in Daily Morning (AM) PEF Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over 12 weeks and 24 weeks of the 24-week Treatment Period (at Weeks 12 and 24) minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 12 and Week 24
Reported as:
Least squares mean · Liters/minute (L/min)
Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
Liters/minute (L/min)PlaceboFF 100 µg ODFP 250 µg BID
AM PEF, Week 1 to 125.7 ± 3.4113.2 ± 3.449.4 ± 3.43
AM PEF, Week 1 to 245.0 ± 3.4513.9 ± 3.489.9 ± 3.47
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods at the End of the 24-week Treatment Period

The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). Similarly, asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods at the End of the 24-week Treatment Period
Percentage of symptom-free 24-hr periodsPlaceboFF 100 µg ODFP 250 µg BID
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods at the End of the 24-week Treatment Period10.4 ± 2.7719.3 ± 2.7919.2 ± 2.78
SecondaryChange From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24

The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the ages of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Weeks 12 and 24 minus the total score at Baseline.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24
Scores on a scalePlaceboFF 100 µg ODFP 250 µg BID
Week 12, n=85, 99, 990.45 ± 0.0780.69 ± 0.0720.73 ± 0.073
Week 24, n=74, 90, 860.51 ± 0.0900.84 ± 0.0820.67 ± 0.084

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the treatment period (up to Week 24).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/115 (1.7%)30/115 (26.1%)
FF 100 µg OD—4/114 (3.5%)37/114 (32.5%)
FP 250 µg BID—1/114 (0.9%)19/114 (16.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboFF 100 µg ODFP 250 µg BID
PyelonephritisInfections and infestations1/1151/1140/114
AbscessInfections and infestations0/1151/1140/114
Escherichia bacteraemiaInfections and infestations0/1151/1140/114
Supraventricular tachycardiaCardiac disorders0/1150/1141/114
Crohn's diseaseGastrointestinal disorders0/1151/1140/114
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1151/1140/114
Epididymal cystReproductive system and breast disorders0/1151/1140/114
MeningitisInfections and infestations1/1150/1140/114
Most frequent other events
Most frequent other events
EventPlaceboFF 100 µg ODFP 250 µg BID
NasopharyngitisInfections and infestations6/1159/1144/114
BronchitisInfections and infestations7/1158/1144/114
Upper respiratory tract infectionInfections and infestations6/1157/1146/114
HeadacheNervous system disorders5/1157/1147/114
PharyngitisInfections and infestations4/1155/1142/114
SinusitisInfections and infestations1/1154/1142/114
Urinary tract infectionInfections and infestations4/1151/1140/114

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF 100 µg ODFP 250 µg BIDTotal
Mean40.3 ± 17.6840.1 ± 16.1741.4 ± 15.6440.6 ± 16.48
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFF 100 µg ODFP 250 µg BIDTotal
Female686372203
Male475142140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboFF 100 µg ODFP 250 µg BIDTotal
African American/African Heritage (HER)23221964
Central/South Asian Heritage1012
Japanese/East Asian HER/South East Asian HER1113
Native Hawaiian or other Pacific Islander1001
White889092270
American Indian or Alaska Native & White1001
Missing0112
08

Study locations

82 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Montgomery, Alabama 36106, United States
  • GSK Investigational Site
    Green Valley, Arizona 85614, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    San Diego, California 92103-8415, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    San Jose, California 95117, United States
  • GSK Investigational Site
    Cutler Bay, Florida 33189, United States
  • GSK Investigational Site
    Edgewater, Florida 32132, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33185, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Albany, Georgia 31707, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Shiloh, Illinois 62269, United States
  • GSK Investigational Site
    Lenexa, Kansas 66215, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Columbia, Missouri 65203, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68123-4303, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Shelby, North Carolina 28152, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Dayton, Ohio 45459, United States
  • GSK Investigational Site
    Franklin, Ohio 45005, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Collegeville, Pennsylvania 19426, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Dallas, Texas 75225, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    San Antonio, Texas 78224, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78251, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Gozée, 6534, Belgium
  • GSK Investigational Site
    Halen, 3544, Belgium
  • GSK Investigational Site
    Hamois (Natoye), 5360, Belgium
  • GSK Investigational Site
    Tremelo, 3120, Belgium
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Schwedt, Brandenburg 16303, Germany
  • GSK Investigational Site
    Eschwege, Hessen 37269, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Erfurt, Thueringen 99084, Germany
  • GSK Investigational Site
    Schmoelln, Thueringen 04626, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 12043, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Debica, 39-200, Poland
  • GSK Investigational Site
    Kielce, 25-751, Poland
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Lomza, 18-400, Poland
  • GSK Investigational Site
    Sopot, 81-741, Poland
  • GSK Investigational Site
    Szczecin, 71-124, Poland
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 022102, Romania
  • GSK Investigational Site
    Bucharest, 050042, Romania
  • GSK Investigational Site
    Bucharest, 050526, Romania
  • GSK Investigational Site
    Bucuresti, 041914, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
09

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 7 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2010
First posted
Jul 12, 2010
Start
Jun 30, 2010
Primary completionActual
Jan 1, 2012
CompletionActual
Jan 16, 2012
Results delay requested
Jul 12, 2012
Results first posted
Aug 8, 2013
Last update
Nov 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01159912
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2010
Start date
Jun 30, 2010
Primary completion
Jan 1, 2012
Completion
Jan 16, 2012
Results posted
Aug 8, 2013
Last update
Nov 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion